Deep Brain Stimulation for Parkinson's Disease
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it mentions that participants must be able to tolerate withholding anti-parkinsonian and/or anti-tremor medications. This suggests you might need to pause these medications during the study.
What data supports the effectiveness of the treatment for Parkinson's Disease?
Deep brain stimulation (DBS) has been shown to significantly improve motor symptoms in Parkinson's disease by targeting specific brain areas like the subthalamic nucleus, which helps control movement. This treatment mimics the effects of levodopa, a common Parkinson's medication, and has been effective in both short-term and long-term studies.12345
Is deep brain stimulation generally safe for humans?
Deep brain stimulation (DBS) is generally considered safe, but it can have complications. Common issues include infections, device malfunctions, and sometimes the need for additional surgery. Serious complications are less common but can include bleeding in the brain and permanent neurological problems.678910
How does deep brain stimulation differ from other treatments for Parkinson's disease?
Deep brain stimulation (DBS) is unique because it involves surgically implanting electrodes in specific brain areas to regulate abnormal brain activity, offering an alternative to medication. Unlike standard treatments, DBS can be personalized with Temporally Optimized Patterned Stimulation (TOPS), which may improve symptom relief and energy efficiency by adjusting the timing of the electrical pulses.34111213
What is the purpose of this trial?
The purpose of this study is to measure the effects of non-regular temporal patterns of deep brain stimulation (DBS) on motor symptoms and neural activity in persons with Parkinson's disease (PD), essential tremor (ET), dystonia or multiple sclerosis (MS). These data will guide the design of novel stimulation patterns that may lead to more effective and reliable treatment with DBS. These data will also enable evaluation of current hypotheses on the mechanisms of action of DBS. Improving our understanding of the mechanisms of action of DBS may lead to full development of DBS as a treatment for Parkinson's disease and may lead to future applications of DBS.
Research Team
Warren M Grill, PhD
Principal Investigator
Duke University
Eligibility Criteria
This trial is for individuals with Parkinson's Disease, Essential Tremor, or Multiple Sclerosis who are neurologically stable and scheduled for Deep Brain Stimulation surgery. Participants must understand the study and consent form. Those unable to perform motor tasks or tolerate medication withdrawal, or with ineffective DBS are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Surgery and Stimulation
Subjects undergo surgery for DBS electrode implantation or IPG replacement, followed by delivery of non-regular temporal patterns of stimulation to measure effects on neural activity and motor symptoms.
Follow-up
Participants are monitored for safety and effectiveness after the surgical procedure and stimulation.
Treatment Details
Interventions
- Symptogenic Stimulation Patterns
- Therapeutic Stimulation Patterns
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
Boston Scientific Corporation
Industry Sponsor
Michael F. Mahoney
Boston Scientific Corporation
Chief Executive Officer since 2016
MBA from Wake Forest University, BBA in Finance from the University of Iowa
Kenneth Stein
Boston Scientific Corporation
Chief Medical Officer since 2020
MD from Harvard Medical School, MMSc in Clinical Investigation from Harvard-MIT Division of Health Sciences and Technology
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator
Emory University
Collaborator
University of Florida
Collaborator